Sopharma AD Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Ognian Donev

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	23.5yrs
CEO ownership	8.1%
Management average tenure	no data
Board average tenure	9.3yrs

Recent management updates

Recent updates

CEO

Ognian Donev (66 yo)

23.5yrs

Tenure

лв723,162

Compensation

Mr. Ognian Ivanov Donev, D.Sc. (Econ.), Ph D., serves as the Executive Chairman at Sopharma AD and Sopharma Trading AD and also served as Chief Executive Officer since September 2021 until November 2021. M...

Board Members

Name	Position	Tenure	Compensation	Ownership
Ognian Donev	Chairman	23.5yrs	лв723.16k	8.09% BGN 177.4m
Vessela Stoeva	Deputy Chairman	no data	лв173.75k	0.000090% BGN 2.0k
Ivan Badinski	Director	5.7yrs	лв252.59k	0.0012% BGN 27.0k
Alexandar Tchaoushev	Independent Director	12.8yrs	лв120.00k	0.24% BGN 5.2m
Bissera Lazarova	Director	2.8yrs	no data	0.012% BGN 264.9k

9.3yrs

Average Tenure

60yo

Average Age

Experienced Board: SPH's board of directors are considered experienced (9.3 years average tenure).

Sopharma AD Management

Management criteria checks 2/4

Key information

Recent management updates

Chairman recently sold zł131k worth of stock

Sopharma AD, Annual General Meeting, Jun 30, 2024

Chairman recently bought zł749k worth of stock

Chairman recently bought zł170k worth of stock

Chairman recently bought zł190k worth of stock

Chairman recently sold zł2.4m worth of stock

Recent updates

Full year 2023 earnings released: EPS: лв0.73 (vs лв0.58 in FY 2022)

New major risk - Revenue and earnings growth

Investor sentiment improves as stock rises 22%

Chairman recently sold zł131k worth of stock

Sopharma AD, Annual General Meeting, Jun 30, 2024

Chairman recently bought zł749k worth of stock

New major risk - Financial position

Third quarter 2023 earnings released: EPS: лв0.12 (vs лв0.20 in 3Q 2022)

Upcoming dividend of лв0.90 per share at 8.5% yield

Now 30% undervalued

Sopharma AD Approves Distribution for the First Half of 2023, Payable on January 22, 2024

Sopharma AD to Report Q3, 2023 Results on Nov 29, 2023

Investor sentiment deteriorates as stock falls 15%

Now 26% undervalued

New minor risk - Shareholder dilution

Investor sentiment improves as stock rises 19%

Chairman recently bought zł170k worth of stock

Sopharma AD to Report Q3, 2023 Results on Oct 30, 2023

Chairman recently bought zł190k worth of stock

Investor sentiment improves as stock rises 16%

Chairman recently sold zł2.4m worth of stock

Sopharma AD (BUL:SFA) acquired a 2.38% stake in Sopharma Buildings REIT-Sofia.

Second quarter 2023 earnings released: EPS: лв0.26 (vs лв0.19 in 2Q 2022)

New minor risk - Shareholder dilution

Sopharma AD (BUL:SFA) signed an agreement to acquire Pharmanova d.o.o.

Chairman recently sold zł673k worth of stock

Investor sentiment deteriorates as stock falls 20%

New minor risk - Dividend sustainability

Investor sentiment improves as stock rises 26%

Upcoming dividend of лв0.60 per share

Sopharma AD Declares Dividend for 2022, Payable on 31 July 2023

First quarter 2023 earnings released: EPS: лв0.27 (vs лв0.17 in 1Q 2022)

Less than half of directors are independent

Full year 2022 earnings released: EPS: лв0.60 (vs лв0.71 in FY 2021)

Investor sentiment improves as stock rises 17%

Sopharma AD, Annual General Meeting, Jun 30, 2023

Sopharma AD to Report Fiscal Year 2023 Results on Mar 29, 2024

Third quarter 2022 earnings released: EPS: лв0.20 (vs лв0.14 in 3Q 2021)

Less than half of directors are independent

Now 20% undervalued after recent price drop

Now 29% undervalued after recent price drop

Second quarter 2022 earnings released: EPS: лв0.19 (vs лв0.12 in 2Q 2021)

Now 27% undervalued

Now 24% undervalued after recent price drop

Now 21% undervalued

Sopharma AD (BUL:SFA) made the offer to acquire remaining 66.66% stake in Sopharma Properties REIT (BUL:SFI) for approximately BGN 120 million.

First quarter 2022 earnings released: EPS: лв0.17 (vs лв0.14 in 1Q 2021)

Less than half of directors are independent

Less than half of directors are independent

Sopharma AD, Annual General Meeting, Jun 03, 2022

Sopharma AD to Report Fiscal Year 2021 Final Results on Apr 29, 2022

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Sopharma AD to Report Fiscal Year 2021 Results on Mar 31, 2022

An unknown buyer has agreed to acquire SIA BRIZ from Sopharma AD (BUL:SFA).

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

Second quarter 2021 earnings released

Chairman recently bought zł182k worth of stock

Less than half of directors are independent

First quarter 2021 earnings released

Revenue beats expectations

Full year 2020 earnings released: EPS лв0.20 (vs лв0.69 in FY 2019)

Investor sentiment improved over the past week

Sopharma AD (BUL:3JR) acquired an unknown minority stake in SIA BRIZ.

Investor sentiment improved over the past week

An unknown buyer acquired majority stake of Aromania OOD from Sopharma AD (BUL:3JR).

Investor sentiment improved over the past week

New 90-day low: zł9.30

Market pulls back on stock over the past week